Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
Isomorphic Labs
AI drug-design company spun out of Google DeepMind, applying AlphaFold-derived models across an end-to-end drug design engine.
Isomorphic Labs, founded in 2021 and headquartered in London, United Kingdom, is an AI-first drug-design company spun out of Google DeepMind. It builds on DeepMind's AlphaFold structural-biology research to develop an end-to-end 'Drug Design Engine' spanning target understanding, molecular generation, and candidate optimization. It operates through pharma partnerships rather than selling a self-serve tool: a drug-design collaboration with Eli Lilly (announced with up to roughly $1.7B in potential milestones) and one with Novartis (roughly $1.2B, expanded in February 2025 to add three additional research programs). The company has raised a Series B and reports approximately $2.7 billion in total funding. No GxP, 21 CFR Part 11, or SOC 2 claim was documented on public pages at profiling time. It is a DeepMind-affiliated but independently operated company, distinct from Google's Gemini product line.
- Headquarters
- London, United Kingdom
- Founded
- 2021
- Deployment options
- cloud
- Website
- https://www.isomorphiclabs.com
- https://www.linkedin.com/company/isomorphic-labs
Categories
AI Use Cases
- Hit Identification & Lead Optimization
- Target Identification & Validation
Vendor Scorecard
79% — Complete coverage. Coverage score — how completely Atlas documents Isomorphic Labs across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Documented
Partnership / milestone based
Implementation & Onboarding — Documented
12+ months
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, Drug Discovery, R&D Leadership
Solution Scope — Documented
Molecular Generation, Protein Structure Prediction, Target Identification
Company Viability — Partially documented
Series B, Founded 2021
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Questions to Ask This Vendor
- What does a research partnership require from our internal target and chemistry data?
- How are IP and data-exclusivity terms structured on jointly discovered compounds?
- What has the Drug Design Engine demonstrated on target classes similar to ours?
- What is the realistic timeline from engagement to a development candidate?